Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Raben

Showing results (1-10 of 161) with videos related to

Pageof 17
Sort By:
JAMA Oncology|January 6, 2022
When Radiotherapy and Immunotherapy Dance-Who Leads So as Not to Step on Toes?Fiyinfolu Balogun, David Raben
Clinical Lung Cancer|December 16, 2005
Vascular-targeting agents and radiation therapy in lung cancer: where do we stand in 2005?David Raben, Anderson Ryan
Clinical Lung Cancer|August 18, 2004
Angiogenesis inhibitors: a rational strategy for radiosensitization in the treatment of non-small-cell lung cancer?David Raben, Barb Helfrich
International Journal of Radiation Oncology, Biology, Physics|September 2, 2021
A Two-Headed Heated DebateDavid Raben, Adam Raben
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Biologically targeted therapies plus chemotherapy plus radiotherapy in stage III non-small-cell lung cancer: a case of the Icarus syndrome?David Raben, Paul A Bunn
Future Oncology (London, England)|August 23, 2006
Toward a unified target theory in oncologyBrian D Kavanagh, David Raben
Oncology (Williston Park, N.Y.)|September 6, 2011
Back to the future: a proton pro/conBrian D Kavanagh, David Raben
Seminars in Radiation Oncology|November 26, 2008
Integrating biologically targeted therapy in head and neck squamous cell carcinomasQuynh-Thu Le, David Raben
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
p16 Expression as a predictive biomarker of hypoxic cell-sensitizing agents in oropharyngeal cancerChristine H Chung, David Raben
The Lancet. Oncology|August 1, 2019
Radioimmunotherapy for the treatment of head and neck cancerSana D Karam, David Raben
Pageof 17

Showing results (1-10 of 161) with videos related to

Sort By:
Pageof 17
JAMA Oncology|January 6, 2022
When Radiotherapy and Immunotherapy Dance-Who Leads So as Not to Step on Toes?Fiyinfolu Balogun, David Raben
Clinical Lung Cancer|December 16, 2005
Vascular-targeting agents and radiation therapy in lung cancer: where do we stand in 2005?David Raben, Anderson Ryan
Clinical Lung Cancer|August 18, 2004
Angiogenesis inhibitors: a rational strategy for radiosensitization in the treatment of non-small-cell lung cancer?David Raben, Barb Helfrich
International Journal of Radiation Oncology, Biology, Physics|September 2, 2021
A Two-Headed Heated DebateDavid Raben, Adam Raben
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Biologically targeted therapies plus chemotherapy plus radiotherapy in stage III non-small-cell lung cancer: a case of the Icarus syndrome?David Raben, Paul A Bunn
Future Oncology (London, England)|August 23, 2006
Toward a unified target theory in oncologyBrian D Kavanagh, David Raben
Oncology (Williston Park, N.Y.)|September 6, 2011
Back to the future: a proton pro/conBrian D Kavanagh, David Raben
Seminars in Radiation Oncology|November 26, 2008
Integrating biologically targeted therapy in head and neck squamous cell carcinomasQuynh-Thu Le, David Raben
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
p16 Expression as a predictive biomarker of hypoxic cell-sensitizing agents in oropharyngeal cancerChristine H Chung, David Raben
The Lancet. Oncology|August 1, 2019
Radioimmunotherapy for the treatment of head and neck cancerSana D Karam, David Raben
Pageof 17